Biodesix, Inc. (NASDAQ: BDSX) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $72M. The Maz Rating grades it against the other companies in its sector.
Biodesix, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.88, Biodesix, Inc. trades at 0.7x sales and 11.0x book value. Over the last twelve months it generated about $104M of revenue and a net loss of $22M. It runs a gross margin of 82.4%, an operating margin of -18.7% and a net margin of -25.7%. It shows return on equity of -442.3%, return on invested capital of -24.0% and a free cash flow yield of -25.8%. On the balance sheet: a debt-to-equity ratio of 8.35 and a current ratio of 2.96. Over the past 52 weeks the share price ranged from $5.26 to $31.97, with a beta of 0.55.
Biodesix, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 8 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Biodesix, Inc. (BDSX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 20.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.5% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 20.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.5% / 33% · Receivables / Mkt Cap (36m) 3.69% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 20.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.5% / 33.33% · Receivables / Mkt Cap (24m) 3.69% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 51.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 27.7% / 33.33% · Receivables / Avg Assets (4Q) 9.93% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 52.5% / 33.33% · (Cash+ST Inv) / Total Assets 30.2% / 33.33% · (Cash+Recv) / Total Assets 39.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Biodesix, Inc. (BDSX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Biodesix, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Biodesix, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.